ClinicalTrials.gov
ClinicalTrials.gov Menu

Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000264
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : May 27, 2015
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
The purpose of this study is to examine the subjective, psychomotor, and reinforcing effects of combined alcohol and nitrous oxide intake in healthy volunteers.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Substance-Related Disorders Drug: 30% Nitrous oxide Other: 0.35 g/Kg ethanol Other: 0.7 g/Kg ethanol Other: 0 g/Kg ethanol Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Crossover Assignment
Masking: Double (Participant, Care Provider)
Official Title: Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide
Study Start Date : September 1997
Actual Primary Completion Date : October 1999
Actual Study Completion Date : October 1999

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: 0 g/Kg ethanol +/- 30% nitrous oxide Drug: 30% Nitrous oxide
Other: 0 g/Kg ethanol
Active Comparator: 0.35 g/Kg ethanol +/- 30% nitrous oxide Drug: 30% Nitrous oxide
Other: 0.35 g/Kg ethanol
Active Comparator: 0.7 g/Kg ethanol +/- 30% nitrous oxide Drug: 30% Nitrous oxide
Other: 0.7 g/Kg ethanol



Primary Outcome Measures :
  1. Mood [ Time Frame: Baseline and post inhalation ]
  2. Psychomotor performance [ Time Frame: Baseline and post inhalation ]
  3. Cognitive performance [ Time Frame: Baseline and post inhalation ]
  4. Choice of nitrous oxide vs placebo [ Time Frame: after each ethanol session ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000264


Locations
United States, Illinois
University of Chicago, Anesthesia & Critical Care
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: James Zacny, Ph.D. University of Chicago

Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT00000264     History of Changes
Other Study ID Numbers: NIDA-08391-16
R01DA008391 ( U.S. NIH Grant/Contract )
R01-08391-16
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: May 27, 2015
Last Verified: May 2015

Keywords provided by University of Chicago:
nitrous oxide
inhalant
ethanol
subjective effects
psychomotor effects
healthy volunteer

Additional relevant MeSH terms:
Disease
Substance-Related Disorders
Opioid-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Ethanol
Nitrous Oxide
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Inhalation
Anesthetics, General
Anesthetics
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents